Indian Markets Rebound Sharply as Dr. Reddy's Soars 7% on USFDA Clearance and Earnings Beat

The Quick Take

• India's Nifty 50 recovered 1.2% in afternoon trading, with Dr. Reddy's Laboratories (+7%) leading the pharma rally.
• USFDA granted final approval to Dr. Reddy's generic formulation for a blockbuster hypertension drug with estimated US revenue of $180M annually.
• Sensex regained the 81,000 level as buying interest returned across pharmaceutical, technology, and banking sectors.
• FII buying of ₹2,100 crore in equity cash markets reversed Monday morning's risk-off outflows.
• The pharma index (Nifty Pharma) rose 2.9%, its best single-session performance in four weeks.

India's equity market staged a sharp afternoon recovery on Monday, erasing much of the morning session's losses triggered by global Nasdaq weakness. The catalyst for the recovery was a combination of company-specific good news in the pharmaceutical sector and a stabilisation of the rupee that reduced FII hedging pressure on Indian equity positions. Dr. Reddy's Laboratories led the recovery with a 7% gain after the company announced USFDA final approval for its Abbreviated New Drug Application for a generic formulation of a major hypertension medication — clearing the path to a US market launch with estimated annual revenue of $180 million.

The USFDA clearance is particularly significant because it covers a product with limited generic competition — only two other generic approvals had been granted for the same molecule, meaning Dr. Reddy's will enter a market with sustainable price discipline rather than immediate erosion from overcrowded competition. Management guided for a Q3 FY27 launch in the US, which would contribute meaningfully to the company's international revenue trajectory. The combination of earnings beat expectations and a regulatory catalyst drove the highest single-day volume for Dr. Reddy's shares in three months.

The broader market recovery reflected a reassessment of the morning's risk-off narrative. Domestic institutional investors continued their pattern of buying on dips, with DIIs recording ₹5,100 crore in net equity purchases for the day — significantly exceeding FII net selling of ₹3,400 crore. The Nifty Bank index, which had lagged in the morning, recovered sharply as HDFC Bank and ICICI Bank rose 1.8% and 2.1% respectively on reports of healthy October credit card and personal loan origination data. The overall picture is of a market with strong domestic support infrastructure that is increasingly resilient to short-term global shocks.

Synthesized from 1 source.